PDS Biotechnology Corp., a clinical stage biopharma company developing immunotherapies, has entered a clinical trial collaboration with a subsidiary of Merck to evaluate the combination of PDS’ lead Versamune-based immunotherapy, PDS0101, with Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), in a Phase II trial. The trial will evaluate the safety and efficacy of the combination in patients with recurrent or metastatic head and neck cancer and high-risk human papillomavirus-16 (HP...